Posts

AbCellera, Silence Therapeutics, and InduPro Raise Significant Funding

on
AbCellera has announced a $200 million public offering of common shares and pre-funded warrants, significantly boosting its capital to fund internal pipeline development and corporate needs. InduPro closed a $77 million Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly, to advance its lead oncology program IDP-001 and broader pipeline. Silence Therapeutics completed a $175 million ADS offering at $13.50 per ADS, intending to use the proceeds to support clinical development of its siRNA candidates and general corporate purposes, extending its runway into 2029. Sources: AbCellera Reports Q2 2026 Business Results InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 Sanofi investit dans la biotech américaine InduPro spécialisée dans l'oncologie InduPro, Inc. announced that it expect...

Boulevard Bio launches with $65M to target IgAN and other autoimmune diseases with quarterly‑dosed BAFF/APRIL bispecific against Vera's Trutakna

on

Definium's LSD-based drug clears bar in first Phase 3 anxiety disorder trial

on

Eli Lilly Takes First Legal Action Against Black Market for Experimental Obesity Drug Retatrutide

on

Vaccine Makers and Experts Reject Trump’s Push to Split MMR Shot

on

BridgeBio Posted Q2 Revenue Beat, but Faces Higher Near‑Term Launch Opex, Morgan Stanley Says – Key Highlights

on

Cullinan and Taiho Report Phase III Win for Zipalertinib–Chemotherapy Combo in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

on

Google’s new wearable health features track insulin resistance trends on Pixel Watch and Fitbit Air

on

Trump Issues Executive Order Overhauling Pediatric Vaccine Recommendations

on

Eli Lilly sues six companies over alleged illegal sales of retatrutide knockoffs

on

Definium Hits Another Phase 3 Homerun with Psychedelic Sea Change for Anxiety

on

Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset alvelestat for AATD-LD

on

From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing – Recent industry trends and challenges

on